Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine
- 1 October 2000
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 6 (10) , 1160-1166
- https://doi.org/10.1038/80506
Abstract
The breaking of immune tolerance against autologous angiogenic endothelial cells should be a useful approach for cancer therapy. Here we show that immunotherapy of tumors using fixed xenogeneic whole endothelial cells as a vaccine was effective in affording protection from tumor growth, inducing regression of established tumors and prolonging survival of tumor-bearing mice. Furthermore, autoreactive immunity targeting to microvessels in solid tumors was induced and was probably responsible for the anti-tumor activity. These observations may provide a new vaccine strategy for cancer therapy through the induction of an autoimmune response against the tumor endothelium in a cross-reaction.Keywords
This publication has 44 references indexed in Scilit:
- Identification of Tek/Tie2 Binding PartnersJournal of Biological Chemistry, 1999
- CD4+ T cells, but not CD8+ T cells, are required for the development of experimental autoimmune gastritisImmunology, 1998
- A Series of Function Blocking Antibodies against the αvβ3 Integrin Bind Allosteric to the Ligand Binding Site and Induce Ligand DissociationCell Adhesion and Communication, 1998
- The Th1/Th2 paradigmImmunology Today, 1997
- Mechanisms of angiogenesisNature, 1997
- T cell selection and autoimmunity: flexibility and tuningCurrent Opinion in Immunology, 1996
- Molecular cloning of Quek 1 and 2, two quail vascular endothelial growth factor (VEGF) receptor-like moleculesGene, 1996
- What Is the Role of Thymidine Phosphorylase in Tumor Angiogenesis?JNCI Journal of the National Cancer Institute, 1996
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990